Clinical Efficacy & Immune Activation Demonstrated By Oncolytic Adenovirus ONCOS-102 In Solid Tumors
Time: 12:30 pm
day: Day One
Details:
- Robust clinical activity of ONCOS-102 in combination with both anti-PD1 and chemotherapy has been observed in several solid tumor types
- ONCOS-102 drives broad and persisting immune responses in responding patients
- Extended dosing regimen drives stronger immune activation and increased systemic activity
